Abstracts tagged "pulmonary"

Abstract Number: 1049 • ACR Convergence 2022
Risk Stratification of Patients with Systemic Sclerosis-associated Pulmonary Arterial Hypertension in EUSTAR Using the Current and New Proposed Criteria
Hilde Jenssen Bjørkekjær¹, cosimo bruni², PATRICIA E CARREIRA³, Paolo Airò⁴, CARMEN PILAR SIMEON⁵, Marie-Elise Truchetet⁶, Alessandro Giollo⁷, Alexandra Balbir-Gurman⁸, Mickaël MARTIN⁹, Chris Denton¹⁰, Armando Gabrielli¹¹, Håvard Fretheim¹², Imon Barua¹², Helle Bitter¹³, Øyvind Midtvedt¹², Kaspar Broch¹⁴, Arne Andreassen¹², Yoshiya Tanaka¹⁵, Gabriela Riemekasten¹⁶, Ulf Müller-Ladner¹⁷, Marco Matucci-Cerinic², Ivan Castellvi¹⁸, Elise Siegert¹⁹, Eric Hachulla²⁰, Oliver Distler²¹ and Anna-Maria Hoffmann-Vold¹², ¹Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, Kristiansand, Norway, ²University of Florence, Florence, Italy, ³HOSPITAL 12 DE OCTUBRE, Madrid, Spain, ⁴Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy, ⁵Hospital Vall D'Hebron, Barcelona, Spain, ⁶CHU de Bordeaux, Bordeaux, France, ⁷Rheumatology Section, Department of Medicine, University of Verona, Italy, Verona, Italy, ⁸Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel, ⁹Poitiers's Universatory Hospital, Department of Internal Medicine, Poitiers, France, Mignaloux-Beauvoir, France, ¹⁰University College London, London, United Kingdom, ¹¹Università Politecnica delle Marche, Ancona, Italy, ¹²Oslo University Hospital, Oslo, Norway, ¹³Sorlandet sykehus, Kristiansand, Norway, ¹⁴Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, Oslo, Norway, ¹⁵University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ¹⁶University Clinic Schleswit-Holstein (UKSH), Luebeck, Germany, ¹⁷JLU Campus KK, Bad Nauheim, Germany, ¹⁸Hospital Universitari de la Santa Creu i Sant Pau, Vilafranca del Pened, Spain, ¹⁹Charité Hospital, Berlin, Germany, ²⁰University of Lille, LILLE, France, ²¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc). A new definition for precapillary PH is proposed. Risk stratification is…
Abstract Number: 1941 • ACR Convergence 2022
Pediatric Idiopathic Pulmonary Hemosiderosis – a Single-Center, Retrospective Study Comparing Use of Commonly Used Steroid-Sparing Agents
Melissa Argraves¹, Melissa Lerman¹, Julie Chase² and Samuel Goldfarb³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Kentucky, Lexington, KY, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Idiopathic Pulmonary Hemosiderosis (IPH) is a rare, pediatric predominant condition causing episodic diffuse alveolar hemorrhage, which can be recurrent and life-threatening. Chronic steroid use…
Abstract Number: 1057 • ACR Convergence 2022
Usefulness of REVEAL 2.0 Score as a Prognosis Tool of All-Cause Pulmonary Hypertension in Systemic Sclerosis Patients: A Multicentric Study
Ivette Casafont-Solé¹, Laura Calvo², Anne Riveros-Frutos³, Carlos De la Puente Bujidos⁴, Pau Alcubilla⁵, Lourdes Mateo¹ and Ivan Castellví⁶, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Universitario Ramon y Cajal, Madrid, Spain, ³Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁴Ramon y Cajal University Hospital, Madrid, Spain, ⁵Hospital Clínic de Barcelona, Barcelona, Spain, ⁶Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
Background/Purpose: Pulmonary arterial hypertension (PAH) leads to a progressive right heart failure and death.PAH is a leading cause of death in Systemic Sclerosis (SSc). To…
Abstract Number: 2160 • ACR Convergence 2022
The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients
Henriette Didriksen¹, Øyvind Molberg², Adi Mehta³, Suzana Jordan⁴, Håvard Fretheim³, Einar Gude³, Thor Ueland³, Cathrine Brunborg³, Vyacheslav Palchevskiy⁵, Torhild Garen³, Øyvind Midtvedt³, Arne Andreassen³, Fridtjof Lund-Johansen³, Oliver Distler⁴, John Belperio⁵ and Anna-Maria Hoffmann-Vold³, ¹Oslo University Hospital, Moss, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Chemokines appear to be important for the pathogenesis of autoimmune diseases. Humans may generate antibodies targeting chemokines leading to inhibition of signaling and driving…
Abstract Number: 1058 • ACR Convergence 2022
Clinical Characteristics and Survival of Combined Pulmonary Arterial Hypertension and Interstitial Lung Disease in Systemic Sclerosis
Jessica Fairley¹, Dylan Hansen², Laura Ross³, Susanna Proudman⁴, Jo Sahhar⁵, Gene-Siew Ngian⁶, Jenny Walker⁷, Lauren Host⁸, Kathleen Morrisroe², Diane Apostolopoulos⁹, Nava Ferdowsi², Michelle Wilson⁹, Maryam Tabesh², Wendy Stevens² and Mandana Nikpour¹⁰, ¹The University of Melbourne, Melbourne, Australia, ²St Vincent's Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ⁴University of Adelaide, Medindie, Australia, ⁵Monash Health, Melbourne, Australia, ⁶Melbourne Health, Northcote, Australia, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Fiona Stanley Hospital, London, United Kingdom, ⁹Monash University, Melbourne, Australia, ¹⁰The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of systemic sclerosis (SSc) associated death. There is increasing interest in…
Abstract Number: 2172 • ACR Convergence 2022
Pulmonary Function in Patients Diagnosed of Early Systemic Sclerosis: 10 Years-Experience
Samuel Leal Rodriguez¹, Francisco Miguel Ortiz Sanjuan², José Ivorra Cortés³, Laura Mas Sanchez³, Pablo Muñoz Martinez⁴, Carmen Riesco Bárcena⁵, Anderson Huaylla Quispe⁶, Cristobal Pavez Perales³, Inés Cánovas Olmos³, Luis Gonzalez Puig⁷, Elena Grau García³, Isabel Martínez-Cordellat³, Carmen Nájera Herranz³, Rosa Negueroles Albuixech³, JOSE ELOY OLLER RODRIGUEZ⁸, Elvira Vicens Bernabeu², Alba Torrat Novés⁵, Daniel Ramos Castro³ and José andrés Román ivorra¹, ¹Hospital Universitari i Politécnic La Fe, València, Spain, ²Hospital Universitario de La Fe, València, ³Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, ⁴Rheumatology Department. Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, ⁶Medicina, València, Spain, ⁷Hospital La Fe, Torrente, Valencia, Spain, ⁸Hospital Universitario de La Fe, València, Spain
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc), often progressive and has a poor prognosis. A restrictive ventilatory defect could…
Abstract Number: 1090 • ACR Convergence 2022
Pulmonary Function Testing (PFT) in Patients with Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis (AAV): Correlation with Radiologic Imaging
Johannes Dieterich¹, You-Shan Feng², Juliane Mahrhold¹, Abdallah El Rai³ and Bernhard Hellmich¹, ¹Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ²Institute for clinical Epidemiology and Biometry, University of Tübingen, Tübingen, Germany, ³Department of Radiology und Nuclear Medicine, Medius Kliniken, University of Tübingen, Nürtingen, Germany
Background/Purpose: Although pulmonary manifestations occur frequently in AAV, empirical evidence of their impact on pulmonary function is scarce. This project analyzed PFT data from a…
Abstract Number: 2175 • ACR Convergence 2022
Evaluation of the Distribution of Haemodynamic Parameters and Prognostic Impact in a Cohort of Patients with Systemic Sclerosis
Zoe Brown¹, Dylan Hansen², Wendy Stevens², Laura Ross¹, Nava Ferdowsi², Susanna Proudman³, Jenny Walker⁴, Jo Sahhar⁵, Gene-Siew Ngian⁶, Lauren Host⁷, Gabor Major⁸, Mandana Nikpour⁹ and Kathleen Morrisroe², ¹St Vincent's Hospital, Melbourne, Australia, ²St Vincent's Hospital Melbourne, Melbourne, Australia, ³University of Adelaide, Medindie, Australia, ⁴Flinders Medical Centre, Flinders University, Daw Park, Australia, ⁵Monash Health, Melbourne, Australia, ⁶Melbourne Health, Northcote, Australia, ⁷Fiona Stanley Hospital, London, United Kingdom, ⁸Hunter New England Health Service, Rankin Park - Newcastle, New South Wales, Australia, ⁹The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Scleroderma (SSc) is a complex multisystem autoimmune disease, characterised by vasculopathy and fibrosis of skin and organs. Involvement of the cardiovascular system occurs frequently…
Abstract Number: 1108 • ACR Convergence 2022
Abnormal Baseline Chest CT Shows Increased Risk for Immune Checkpoint Inhibitor Associated Pneumonitis
Danielle Stahlbaum¹, Renea Jablonski¹, Mary Strek² and Pankti Reid¹, ¹University of Chicago Medical Center, Chicago, IL, ²University of Chicago, Chicago, IL
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in off-target toxicities known as immune-related adverse events (irAEs). With increased use of…
Abstract Number: 2176 • ACR Convergence 2022
Novel Tissue Turnover Blood Markers Are Associated with Pulmonary Arterial Hypertension and NYHA Stages in Patients with Systemic Sclerosis
Signe Holm Nielsen¹, Sine Søndergaard Korsholm², Axel Diederichsen³, Morten Karsdal¹, John Bonde Knudsen⁴, Anne-Christine Bay-Jensen¹, Louise Diederichsen⁵ and Christoffer Tandrup Nielsen⁶, ¹Nordic Bioscience, Herlev, Denmark, ²Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Dept of Rheumatology, Odense University Hospital (OUH), Odense, Denmark, ³Dept of Cardiology, OUH, Odense, Denmark, Odense, ⁴Dept of Rheumatology, OUH, Odense, Denmark., Odense, ⁵Copenhagen University Hospital, Rigshospitalet, Dragør, Denmark, ⁶Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Systemic sclerosis (SSc) is characterized by vasculopathy and fibrosis of the skin and internal organs. Cardiac involvement, pulmonary arterial hypertension (PAH), and interstitial lung…
Abstract Number: 0075 • ACR Convergence 2022
Real-World Treatment Patterns Among Patients with Connective Tissue Disorder–Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis
Yuen Tsang¹, Marjolaine Gauthier-Loiselle², Vienica Funtanilla³, Hayley Germack³, Ameur Manceur⁴, Stephanie Liu², Martin Cloutier², Patrick Lefebvre² and Sumeet Panjabi⁵, ¹Janssen Scientific Affairs, LLC., Sacramento, CA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Janssen Scientific Affairs, LLC, Titusville, NJ, ⁴Analysis Group, Inc, Boston, MA, ⁵Analysis Group, Inc., Titusville, NB, Canada
Background/Purpose: Connective tissue disorders (CTDs) are the most frequent diseases associated with pulmonary arterial hypertension (PAH), accounting for 11% – 28% of PAH cases. A…
Abstract Number: 1110 • ACR Convergence 2022
Solving Sarcoidosis: A Transcriptome-based Meta-analysis of Clinical Sarcoidosis Studies Illustrates Shared Pathophysiology, Identifies Candidate Biomarkers and Suggests a Therapeutic Mechanism of JAK Inhibition
Ingrid Lindquist¹, James T. Rosenbaum² and Marcia Friedman³, ¹Oregon Health and Science University, Portland, OR, ²Legacy Devers Eye Institute, Portland, OR, ³Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR
Background/Purpose: Sarcoidosis is a systemic, non-caseating granulomatous disease driven by a dysregulated immune response to environmental antigens. A wide range of clinical manifestations coupled with…
Abstract Number: 0124 • ACR Convergence 2022
Evaluation of Comorbidity Burden and Its Effect on Lung Disease Progression and Mortality in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features
Elena Joerns¹, Michelle Ghebranious¹, Traci Adams¹ and Una Makris², ¹UT Southwestern, Dallas, TX, ²UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease (ILD) which manifests with interstitial pneumonia and features of autoimmunity, yet…
Abstract Number: 1282 • ACR Convergence 2022
Practice Patterns for Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Among Nephrologists and Rheumatologists – an International Survey Study
Swati Arora¹, Brad Rovin² and Tanmayee Bichile³, ¹Allegheny Health Network, Pittsburgh, ²The Ohio State University, Columbus, OH, ³Allegheny Health Network, Gibsonia, PA
Background/Purpose: Patients with autoimmune disorders such as systemic lupus erythematosus (SLE), lupus nephritis (LN) and granulomatosis with polyangiitis (GPA) frequently require treatment with immunosuppressive drugs.…
Abstract Number: 0140 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Müller⁶, Carl Coeck⁷, Klaus Rohr⁸ and Wim Wuyts⁹, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁷Boehringer Ingelheim SComm, Brussels, Brussels, Belgium, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital…

« Previous Page
1
…
8
9
10
11
12
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].